$CDNA

Novack Jeffrey Adam sold $124K of CDNA

Novack Jeffrey Adam (Secretary and General Counsel) sold 2,688 shares of CareDx, Inc. (CDNA) at an average of $46.26 ($46.15–$46.75, $0.12M total) across 2 trades on 2026-08-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Novack Jeffrey Adam
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:46 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CDNA
Neutral
high confidence
Mentioned
$CDNA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and post-transaction holdings by the company’s Secretary and General Counsel under a 10b5-1 plan.

02

Market read

Traders may note insider selling, but 10b5-1 structure typically reduces signal strength versus discretionary sales.

03

What to watch

The filing does not indicate intent beyond the pre-arranged plan, and the article lacks any accompanying company-specific negative development.

Relevance 3/10Novelty 3/10Timing: filed Aug 6, transaction dated Aug 5

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA).

Company-level read

Ticker impact

$CDNANeutralHigh confidence
Context

CareDx Form 4 shows insider (Secretary and General Counsel) sold 2,688 shares in open-market trades under a 10b5-1 plan on Aug 5.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other negative company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new fundamentals beyond the sale details.

Market effects

No clear sector read-through from a single routine 10b5-1 sale.

None.

None.

Counterpoint

10b5-1 sales can be misread as bearish; the plan timing may be unrelated to near-term performance expectations.

Key entities

  • CareDx, Inc.

    Subject of the Form 4 insider transaction disclosure (CDNA).

  • Novack Jeffrey Adam

    Secretary and General Counsel who sold 2,688 shares under a 10b5-1 plan.

Related articles

$CDNAMedAI 8/10

CareDx Q2 Earnings Call Highlights

CareDx (NASDAQ:CDNA) provided Q2 earnings call guidance. Full-year testing volume is forecast at 258,000 to 266,000 tests and testing-services revenue around $400 million, including $24 million specialty oncology. Patient and digital revenue is expected at $72 million, lab products $23 million, and non-GAAP gross margin 71% to 73%. The company also discussed Medicare LCD coverage, Q3 and Q4 test assumptions, and pipeline updates for AlloHeme and HistoMap.

$CDNAHighAI 9/10

Why CareDx Stock Jumped Today

CareDx (CDNA) shares rose 14.72% after the company raised its full-year sales and earnings outlook. In Q2, revenue grew 52% to $132 million and adjusted net income rose to $20 million, or $0.37 per share. CareDx increased FY revenue guidance to $490M-$500M and EBITDA to $66M-$78M, citing demand and reimbursement coverage.

$CDNAHigh

CareDx, Inc. (CDNA): Results of Operations and Financial Condition

CareDx, Inc. (CDNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cdna-20260730_earningsrele.htm EX-99.1 Document Exhibit 99.1 CareDx Announces Second Quarter 2026 Financial Results Second Quarter Revenue Growth of 52% to $132 Million Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66

$CDNAMedAI 8/10

Why Is CareDx Stock Skyrocketing Thursday? - CareDx (NASDAQ:CDNA)

CareDx (NASDAQ:CDNA) said a finalized Medicare policy preserves coverage for its transplant surveillance tests. The company reported its shares rose nearly 29% after the announcement. Medicare will cover AlloSure Kidney surveillance up to six tests in year one and four annually in years two and three, with similar maintained coverage for AlloMap/AlloSure Heart and AlloSure Lung, plus unchanged for-cause testing.